Michael S. Brown - 02 Jan 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/ Michael S. Brown
Issuer symbol
REGN
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 16:10:05 UTC
Previous filing
06 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BROWN MICHAEL S Director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN /s/ Michael S. Brown 06 Jan 2026 0001174475

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Award $0 +155 +10% $0.000000 1,703 02 Jan 2026 Direct F1
holding REGN Common Stock 5,000 02 Jan 2026 by SLAT F2
holding REGN Common Stock 6,162 02 Jan 2026 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +1,962 $0.000000 1,962 02 Jan 2026 Common Stock 1,962 $772.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2 These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.